Wellgistics Q3 net loss widens to $33.9M ($0.46/share) on stock-based comp

Wellgistics Health, Inc.

2025-Q3 EPS reported -$1.18 revenue$21,667,212

Q3 2025 net operating loss $33.878M vs $1.867M in Q3 2024; net loss per share $0.46 vs $0.04.
Loss driven by increased stock-based compensation related to pre-IPO acquisition of pharmaceutical distribution unit.
President/Interim-CEO Prashant Patel reappointed Oct 6; refocusing on EinsteinRx and Brenzavvy diabetes launch.
Acquisition of Peek Healthcare Technologies terminated as no longer strategically aligned.
Advanced discussions with DataVault AI (DVLT) for blockchain license in Q4 2025/Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.